行情

AGEN

AGEN

安帝君斯
NASDAQ

实时行情|Nasdaq Last Sale

3.720
-0.020
-0.53%
盘后: 3.720 0 0.00% 16:27 11/15 EST
开盘
3.780
昨收
3.740
最高
3.785
最低
3.580
成交量
145.56万
成交额
--
52周最高
4.010
52周最低
1.950
市值
5.11亿
市盈率(TTM)
-3.7940
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AGEN 新闻

  • Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss
  • Zacks.3天前
  • Agenus to Host R&D Day November 15, 2019
  • PR Newswire.4天前
  • Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat
  • Zacks.4天前
  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.4天前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

AGEN 简况

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
展开

Webull提供Agenus Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。